Abstract: By introducing at least one cysteine residue based on wild-type IL-2, the binding plane of the IL-2 derivative and ? receptor subunit is partially or completely blocked, while the affinity of the IL-2 derivative to the complex of ? and ? receptor subunits is basically retained. A complex includes an IL-2 derivative, which is introduced with a third cysteine residue based on wild-type IL-2; and a blocking module, which has or is introduced with a fourth cysteine residue. The third cysteine residue on the IL-2 derivative and the fourth cysteine residue on the blocking module are capable of forming an intermolecular disulfide bond, thereby forming a complex of the IL-2 derivative and the blocking module. The binding plane of the IL-2 derivative and ? receptor subunit is partially or completely blocked, while the affinity of the IL-2 derivative to the complex of ? and ? receptor subunits is basically retained.

Abstract: The present disclosure provides a dental orthodontic appliance and a design method and a manufacturing method thereof. The dental orthodontic appliance includes a shell-like body, and the shell-like body is provided with a plurality of cavities for accommodating maxillary teeth, and the shell-like body is further provided with an upper palatal arch that reshapes a form of a dental arch. Two ends of the upper palatal arch are respectively and partially connected to positions of gingival margins or positions adjacent to the gingival margins on ligual sides in posterior regions of left and right sides of the shell-like body. When the shell-like body interacts with teeth, the upper palatal arch can induce buccolingual lateral amplification of maxillary palatal suture bone deposition by means of deformation, and teeth in the posterior regions move laterally buccolingually under an action of the shell-like body.

Abstract: The present invention discloses an application of neuraminidase and inhibitors thereof in myocardial ischemia and myocardial infarction, provides a correlation between neuraminidase and myocardial ischemic damage to prove the myocardial ischemic damage can be alleviated by inhibiting the activity of neuraminidase, and to prove the neuraminidase can be used as a target for screening drugs for preventing, alleviating and/or treating myocardial ischemic damage. The present invention also demonstrates the alleviating effect of neuraminidase inhibitors on myocardial ischemic damage. Neuraminidase inhibitors improves myocardial ischemic damage by reducing the level of neuraminidase. The present invention further provides a pharmaceutical preparation comprising neuraminidase inhibitor(s) and pharmaceutically acceptable carrier(s), the pharmaceutical preparation can be used for reducing the level of neuraminidase, thus improving myocardial ischemic damage.

Abstract: The present invention discloses an application of neuraminidase and inhibitors thereof in myocardial ischemia and myocardial infarction, provides a correlation between neuraminidase and myocardial ischemic damage to prove the myocardial ischemic damage can be alleviated by inhibiting the activity of neuraminidase, and to prove the neuraminidase can be used as a target for screening drugs for preventing, alleviating and/or treating myocardial ischemic damage. The present invention also demonstrates the alleviating effect of neuraminidase inhibitors on myocardial ischemic damage. Neuraminidase inhibitors improves myocardial ischemic damage by reducing the level of neuraminidase. The present invention further provides a pharmaceutical preparation comprising neuraminidase inhibitor(s) and pharmaceutically acceptable carrier(s), the pharmaceutical preparation can be used for reducing the level of neuraminidase, thus improving myocardial ischemic damage.